

Non-invasive investigation of liver disease in haemophilic patients

ELIZABETH J MILLER,* CHRISTINE A LEE,* P KARAYIANNIS†
S J HAMILTON-DUTOIT,‡ R DICK,¶ H C THOMAS,† P B A KERNOFF*

*From the Academic Departments of *Haematology, †Medicine and ‡Histopathology and the ¶Department of Radiology, Royal Free Hospital School of Medicine and Royal Free Hospital, London*

SUMMARY Liver biopsy specimens previously taken from 16 haemophilic patients with chronic non-A, non-B hepatitis were reviewed. The degree of fibrosis correlated with serum procollagen III peptide (sPIIP) concentrations, measured both at the time of biopsy and 4.25 years later. Two patients with extremely high sPIIP concentrations had collateral veins on computed tomography, suggesting portal hypertension. Twenty eight of 47 patients (60%) had splenomegaly on computed tomography, and of 28 patients in whom intravenous contrast medium was used, seven (25%) had collateral oesophageal veins.

Serum procollagen III peptide estimations and computed tomography, both non-invasive investigations, indicated that hepatic fibrosis and portal hypertension had developed in a proportion of haemophilic patients with non-A, non-B hepatitis. Infection with the human immunodeficiency virus (HIV) may modify the course of this presumably cytopathic virus infection of the liver.

Liver function tests are often abnormal in patients with haemophilia who have received coagulation factor concentrates.¹⁻⁴ Liver biopsy in patients with haemophilia carries an increased risk,⁵ and consequently there have been few reports of serial liver biopsy specimens taken from this group of patients.^{6,7}

The aim of this study was to use two non-invasive methods to assess the progression of liver disease in haemophilic patients. Computed tomograms, both with and without intravenous contrast, were used to measure portal vein diameter, the size of the liver and the spleen, and to detect the presence of collateral veins. Serum procollagen III peptide (sPIIP) concentrations which have been shown to reflect the inflammatory activity and degree of established fibrosis in patients with chronic liver disease,⁸ were correlated with the histological findings from a series of liver biopsy specimens taken from 16 patients between July 1978 and April 1983, and with abdominal computed tomograms.

Patients and methods

Liver biopsies had been performed on 16 patients with chronic non-A, non-B hepatitis between 1978 and 1983.⁹ The median age at the time of biopsy was 32.5

years (range 9-61 years). Fourteen patients had severe haemophilia A, one had moderate haemophilia B, and one was a female carrier of haemophilia A. In 1984 (an average of 4.25 years later, range one-six), these patients had the progression of their liver disease evaluated by abdominal computed tomogram enhanced by contrast medium to measure the size of the liver and the spleen, and the diameter of the portal vein, and to detect the presence or absence of collateral veins. Three patients had repeat computed tomograms carried out in 1986.

An additional 32 patients, 28 with severe haemophilia A, one with mild haemophilia A, two with haemophilia B (one mild and one severe), and one with severe von Willebrand's disease, had abdominal computed tomograms carried out between 1983 and 1986. The median age was 28 years at the time of the computed tomogram (range 13-65). All had evidence of persistently or intermittently raised aspartate transaminase (AST) activity (>40 iu/l) for at least 12 months.

Computed tomograms were carried out in 12 patients who did not have liver disease but who had the scans for other reasons. The median age was 57 years (range 37-71).

For the unenhanced abdominal computed tomogram, slices 8 mm thick were taken from the diaphragm to the lower border of the liver and spleen. There was a 15 mm table feed. For the enhanced

Table Procollagen III peptide (PCP) in 16 patients with haemophilia

Patient	Age at biopsy	Diagnosis	Liver histology	Degree of fibrosis scale 0-3	sPIIIP at liver biopsy ng/ml	sPIIIP at CT ng/ml	Varices on CT	Portal vein diameter (repeated 1986)
1	22	VIII < 1%	CLH	0	11.9	11.6	No	1.2
2	23	VIII < 1%	CPH	1	13.1	33.1	No	—
3	18	VIII < 1%	CPH	1	36.8	23.2	Yes	1.4
4	19	VIII < 1%	CPH	1	34.0	17.8	No	1.7
5	29	VIII < 1%	CAH mild	1	36.3	20.7	No	1.4
6	54	VIII < 16%	CAH mild	1	26.5	20.7	No	1.1
*7	41	VIII < 1%	CAH mild	1	13.1	30.5	Yes	2.0
8	18	VIII < 1%	CAH mild	1	21.9	27.6	No	2.5 (1.2)
9	27	IX 3%	CAH mild	1	ND	11.6	No	1.2
10	32	VIII < 1%	CAH mild	1	19.5	15.4	Yes	1.0
11	16	VIII < 1%	CAH mild	1	36.3	77.3	No	1.0
12	53	VIII < 1%	CAH mild	2	21.9	44.6	No	(1.6)
13	61	VIII < 1%	CAH mild	3	21.9	120	Yes	1.5 (1.1)
14	57	VIII < 1%	CAH moderate	2	32.0	10.9	No	1.2
15	51	VIII < 1%	CAH moderate	3	20.6	22.3	No	1.5
*16	49	VIII < 1%	CAH moderate	3	23.4	107	Yes	1.4

*Died of AIDS

CLH = Chronic lobular hepatitis

CPH = Chronic persistent hepatitis

CAH = Chronic active hepatitis

abdominal computed tomogram, 100 ml 10 hexol (Omnipaque 350) was injected intravenously, 50 ml as a bolus and 50 ml as an infusion during the scan sequence. The first scan was taken at the level of the portal vein to ensure maximum concentration, and continued to the lower border of the liver and spleen. The upper liver and oesophagus were then scanned using 8 mm thick slices; a 15 mm table feed was again used. The portal vein was measured at its maximum diameter.

A radioimmunoassay (RIA-gnost procollagen-III-peptide, Hoechst, Marburg, Germany) was used to measure sPIIIP in the 16 patients who had had their livers biopsied. Measurements were made within six months of the biopsy and at the time of the computed tomogram. All serum samples were stored at -40°C until assayed.

Liver biopsies had been performed to assess chronically raised aspartate transaminase activities. The specimens were reviewed without knowledge of the other data by the histopathologist. The degree of fibrosis was graded (0 = none, 1 = portal expansion, 2 = septa, 3 = linkage of structures, 4 = cirrhosis).

HIV antibody was assayed using a commercially available competitive enzyme immunoassay (Wellcozyme, Wellcome Diagnostics, Dartford, England).

Statistical analysis of the data was by the non-parametric Mann-Whitney U test, using the Minitab statistical package.

Results

The results of examination of the biopsy specimens have previously been reported.⁹ After review the final histological diagnoses of the 16 were: chronic lobular hepatitis (n = 1); chronic persistent hepatitis (n = 3);

mild chronic active hepatitis (n = 9); and moderate chronic active hepatitis (n = 3) (table).

One biopsy specimen in case 1 showed no fibrosis and the sPIIIP concentration was within normal limits (normal range 7-12 ng/ml). Seven of nine liver biopsy specimens that showed grade 1 fibrosis, both liver




Fig 1 Findings on computed tomography and procollagen III peptide concentrations in 16 haemophilic patients who had had liver biopsy specimens taken.

have suggested that the liver disease is normally not progressive.⁶

Biopsy in this group of patients has an increased risk: there is a reported mortality of 1% compared with 0.01% in non-haemophilic patients.⁵ When a liver biopsy specimen cannot be obtained, serum markers of increased collagen synthesis may be used to assess the risk of progression to cirrhosis. Frei *et al* concluded that measurement of the sPIIP "reliably reflects activity and degree of liver fibrosis".¹² In this group of haemophilic patients, however, although the sPIIP concentration was abnormal in all but one patient who had chronic lobular hepatitis—and, by definition, no fibrosis—there was no correlation between the concentration of sPIIP and degree of fibrosis. Thus although the concentration of sPIIP reflects inflammatory changes in the liver it cannot be considered as an absolute index of hepatic fibrosis.¹³ Weigand *et al* have shown that a persistent rise in the sPIIP concentration suggests continuing fibrosis and developing cirrhosis.¹⁴ In this study the two patients who showed considerable increases in sPIIP concentrations had grade 3 fibrosis and had progressed to varices that were visible on computed tomogram. It is noteworthy that this information was obtained without the risk of repeat liver biopsy. Subsequently, evidence for progression of liver fibrosis was shown by the finding of cirrhosis at necropsy thus confirming the prediction of the sPIIP concentrations.

The dominant causative agents for hepatitis in the haemophilic patient are thought to be non-A, non-B hepatitis viruses.^{9,15} These viruses are probably cytopathic¹⁶ and in the presence of concurrent infection with HIV, which is immunosuppressive, there is likely to be acceleration of the underlying liver disease. It is therefore relevant that of the two patients who died from AIDS, both had varices and one had cirrhosis together with an extremely high sPIIP concentration. Conversely, those patients who were seronegative for HIV did not have high concentrations of sPIIP, and the sizes of the livers and spleens were normal. Thus the HIV retrovirus is yet another virus that may have a modulating influence on the hepatitis occurring in haemophilic patients.¹⁷

Computed tomograms were helpful in assessing these patients, and a high incidence of splenomegaly and hepatomegaly was found. A similar result was reported in haemophiliacs by Johnson *et al*.¹⁸ This may represent progressive liver disease with portal hypertension, but the continued injection of clotting factor concentrates containing a variety of antigens may also contribute to splenomegaly. The extra hepatic portal venous system can be shown with post contrast computed tomography (CCT).¹⁹ The high incidence of oesophageal varices shown by this technique suggests that these patients had developed portal hypertension.

This is consistent with the observation of Hay *et al* that progressive liver disease is now a problem in patients with haemophilia.⁷

Ultrasound scans have been used to measure the diameter of the portal vein for the non-invasive diagnosis of extra hepatic portal venous obstruction²⁰ but we know of no previous report of the use of CCT. Weinreb *et al* suggested that a portal vein diameter greater than 13 mm is a characteristic sign of portal hypertension.²¹ In this group of haemophilic patients the measurement of the diameter of the portal vein was not useful in diagnosing portal hypertension.

The most reliable investigation for assessing the extent of liver fibrosis is still the examination of the liver biopsy specimen by an experienced histopathologist. In haemophilic patients, however, in whom progression of the liver disease may occur over many years, follow up with repeated liver biopsy carries a risk. For the patient with haemophilia even endoscopy is a comparatively invasive procedure, and therefore injection of contrast medium to establish the presence of varices is justified and helpful. In our study sPIIP measurement together with computed tomograms have provided evidence of progression of liver disease in patients with haemophilia.

We thank the staff of the Royal Free Hospital computed tomography department, Professor Peter Scheuer for his helpful comments, Dr Paul Griffiths for the measurement of HIV antibodies, and Mrs Valerie Lee for typing the manuscript.

References

- 1 Levine PH, McVerry BA, Attock B, Dormandy KM. Health of the intensively treated haemophiliac, with special reference to abnormal liver chemistries and splenomegaly. *Blood* 1977;**50**: 1-19.
- 2 Mannucci PM, Capitanio A, Del Ninno E, Colombo M, Pareti F, Ruggeri ZM. Asymptomatic liver disease in haemophiliacs. *J Clin Pathol* 1975;**28**:620-4.
- 3 Preston FE, Triger DR, Underwood JCE, *et al*. Percutaneous liver biopsy and chronic liver disease in haemophiliacs. *Lancet* 1978;ii:592-94.
- 4 Spero JA, Lewis JH, Van Thiel DH, Hasiba U, Rabin BS. Asymptomatic structural liver disease in haemophilia. *N Engl J Med* 1978;**298**:1373-8.
- 5 Aledort LM, Levine PH, Hilgartner M, *et al*. A study of liver biopsies and liver disease among haemophiliacs. *Blood* 1985;**66**:367-72.
- 6 Mannucci PM, Colombo M, Rizzetto M. Non progressive course of non-A, non-B chronic hepatitis in multitransfused haemophiliacs. *Blood* 1982;**60**:655-8.
- 7 Hay CRM, Preston FE, Triger DR, Underwood JCE. Progressive liver disease in haemophilia: an understated problem? *Lancet* 1985;i:1495-8.
- 8 Rojkind M. The blue glass and the predictive value of serum amino-terminal propeptide of type III procollagen as a marker of liver fibrosis. *Hepatology* 1984;**4**:977-8.

Non-invasive investigation of liver disease in haemophilic patients

1043

- 9 Bamber M, Murray A, Arborgh BAM, *et al*. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. *Gut* 1981;22:854-9.
- 10 White GC, Zeitler KD, Lesesne HR, *et al*. Chronic hepatitis in patients with haemophilia A: histological studies in patients with intermittently abnormal liver function tests. *Blood* 1982;60:1259-62.
- 11 Review by an International Group. Acute and chronic hepatitis revisited. *Lancet* 1977;ii:914-9.
- 12 Frei A, Zimmerman A, Weigand K. The N terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. *Hepatology* 1984;4:830-4.
- 13 Surrenti C, Casini A, Milani S, Ambus S, Ceccatelli P, D'Agata A. Is determination of serum N-terminal procollagen type III peptide (sPIIIP) a marker of hepatic fibrosis? *Dig Dis Sci* 1987;32:705-9.
- 14 Weigand K, Zaugg P, Frei A, Zimmerman A. Longterm follow up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. *Hepatology* 1984;4:835-8.
- 15 Craske J, Spooner RJD, Vandervelde EM. Evidence for existence of at least two types of factor-VIII-associated non B transfusion hepatitis. *Lancet* 1978;ii:1051-2.
- 16 Diennes HP, Popper H, Manns M, *et al*. New morphological aspects of auto immune hepatitis (AIH). *Hepatology* 1986;6:1226.
- 17 Lee CA, Kernoff PBA, Karayiannis P, Farci P, Thomas HC. Interactions between hepatotropic viruses in patients with haemophilia. *Hepatology* 1985;1:379-84.
- 18 Johnson RJ, Zhu XP, Isherwood I, *et al*. Computed tomography: qualitative and quantitative recognition of liver disease in haemophilia. *J Comput Assist Tomogr* 1983;7:1000-6.
- 19 Foley WD, Varma RR, Lawson TL, Berland LL, Smith DF, Thorsen K. Dynamic computed tomography and duplex ultrasonography: *J Comput Assist Tomogr* 1983;7:77-82.
- 20 Webb LJ, Berger LA, Sherlock S. Grey scale ultrasound of portal vein. *Lancet* 1977;ii:675-7.
- 21 Weinreb J, Kumari S, Phillips G, Pochaczewsky R. Portal vein measurements by real-time sonography. *AJR* 1982;139:497-9.

Requests for reprints to: Dr Christine A Lee, Haemophilia Centre, Royal Free Hospital, Pond Street, London NW3 2QG, England.



Non-invasive investigation of liver disease in haemophilic patients.

E J Miller, C A Lee, P Karayiannis, et al.

J Clin Pathol 1988 41: 1039-1043

doi: 10.1136/jcp.41.10.1039

Updated information and services can be found at:

<http://jcp.bmj.com/content/41/10/1039>

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://journals.bmj.com/cgi/ep>